Amgen’s Tarlatamab Gets FDA Priority Review for Small Cell Lung Cancer
122 بار بازدید -
7 ماه پیش
-
For more on this story:
For more on this story: https://xtalks.com/amgens-tarlatamab-...
In today's life sciences news, the US FDA has given priority review status to Amgen’s drug candidate, tarlatamab. This new therapy is designed to treat small cell lung cancer in patients who have progressed following treatment with chemotherapy. According to Amgen's executive VP of R&D, "The FDA’s Priority Review designation for this application underscores the urgency to provide new treatment options for patients with advanced small cell lung cancer.”
#fda #clinicaltrials #clinicalresearch #oncology #cancer #amgen #lungcancer #PriorityReview
In today's life sciences news, the US FDA has given priority review status to Amgen’s drug candidate, tarlatamab. This new therapy is designed to treat small cell lung cancer in patients who have progressed following treatment with chemotherapy. According to Amgen's executive VP of R&D, "The FDA’s Priority Review designation for this application underscores the urgency to provide new treatment options for patients with advanced small cell lung cancer.”
#fda #clinicaltrials #clinicalresearch #oncology #cancer #amgen #lungcancer #PriorityReview
7 ماه پیش
در تاریخ 1402/10/08 منتشر شده
است.
122
بـار بازدید شده